We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Faced with a pair of phase 2 failures, Realm Therapeutics has abandoned the platform that underlies all its drug development programs and engaged advisers to look into a possible sale...